nach oben

International Journal of Clinical Oncology

Erschienen in:

01.10.2012 | Original Article

Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection

verfasst von: Yusuke Okuma, Naoki Yanagisawa, Yusuke Takagi, Yukio Hosomi, Akihiko Suganuma, Akifumi Imamura, Mari Iguchi, Tatsuru Okamura, Atsushi Ajisawa, Masahiko Shibuya

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Lung cancer has emerged as a crucial problem among human immunodeficiency virus (HIV)-infected patients, contributing to significant mortality in Western countries. Japan has an increasing number of newly infected HIV patients, but clinical characteristics of lung cancer have not been well investigated in Asian populations with HIV.

Patients and methods

We retrospectively analyzed patients diagnosed with HIV and lung cancer simultaneously in our institution between 1985 and 2010. Data regarding HIV status, characteristics, treatment, and prognosis of lung cancer were evaluated.

Results

We identified 13 consecutive patients (all men; mean age, 59.0 ± 10.2 years) since 1985, 7 of whom had been diagnosed since 2008. Mean CD4 cell count was 332 ± 159 cells/μL, and HIV viral loads were undetectable in 8 patients (61.5%) at the time of lung cancer diagnosis. The mean latency from HIV diagnosis to detection of lung cancer was 4.0 years. Histological examination demonstrated adenocarcinoma in 9 patients (69.2%), followed by squamous cell carcinoma (23.1%), and small cell carcinoma (7.7%). Among the 7 patients available for examination, 2 patients (28.6%) harbored EGFR mutation. Six patients had stage IA–IIIA, and 7 patients had stage IIIB/IV. Among 6 patients treated with chemotherapy for unresectable stages, 5 (83.3%) achieved a partial response. Median overall survival was 17 months for all stages and 14 months for advanced stages. Toxicities for treatment modalities were largely acceptable.

Conclusions

Clinical characteristics of Japanese HIV-infected patients with lung cancer resemble those of Western populations. The prognosis for patients in the metastatic stage was better than previously reported.

Crum-Cianflone N, Hullsiek KH, Marconi V et al (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23:41–50PubMedCrossRef

Engels EA, Brock MV, Chen J et al (2006) Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 24:1383–1388PubMedCrossRef

Engels EA, Pfeiffer RM, Goedert JJ et al (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20:1645–1654PubMedCrossRef

Herida M, Mary-Krause M, Kaphan R et al (2003) Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447–3453PubMedCrossRef

Sridhar KS, Flores MR, Raub WA Jr et al (1992) Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest 102:1704–1708PubMedCrossRef

Tirelli U, Spina M, Sandri S et al (2000) Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 88:563–569PubMedCrossRef

Vyzula R, Remick SC (1996) Lung cancer in patients with HIV infection. Lung Cancer 15:325–339

Azzoli CG, Baker S Jr, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–6266PubMedCrossRef

Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899–909CrossRef

10.

Kirk GD, Merlo C, O’Driscoll P et al (2007) HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 45:103–110PubMedCrossRef

11.

Powles T, Bower M (2004) HIV and the risk of lung cancer. J Clin Oncol 22:1348–1349 (author reply 1349–1350)PubMedCrossRef

12.

Petoumenos K, Hui E, Kumarasamy N et al (2010) Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. J Int AIDS Soc 13:51PubMedCrossRef

13.

Lavole A, Chouaid C, Baudrin L et al (2009) Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 65:345–350PubMedCrossRef

14.

Frisch M, Biggar RJ, Engels EA et al (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA 285:1736–1745PubMedCrossRef

15.

Cinti SK, Gandhi T, Riddell J 4th (2008) Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier? AIDS Read 18(18–20):26–32

16.

Grulich AE, van Leeuwen MT, Falster MO et al (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67PubMedCrossRef

17.

Wistuba II, Behrens C, Milchgrub S et al (1998) Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 279:1554–1559PubMedCrossRef

18.

Bower M, Powles T, Nelson M et al (2003) HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 17:371–375PubMedCrossRef

19.

Samet JM, Wiggins CL, Humble CG et al (1988) Cigarette smoking and lung cancer in New Mexico. Am Rev Respir Dis 137:1110–1113PubMedCrossRef

20.

The National Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. doi:10.1056/NEJMoa1102873

21.

White CS, Haramati LB, Elder KH et al (1995) Carcinoma of the lung in HIV-positive patients: findings on chest radiographs and CT scans. AJR Am J Roentgenol 164:593–597PubMed

22.

Grubb JR, Moorman AC, Baker RK et al (2006) The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 20:1095–1107PubMedCrossRef

23.

Brock MV, Hooker CM, Engels EA et al (2006) Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 43:47–55PubMedCrossRef

24.

Chaturvedi AK, Pfeiffer RM, Chang L et al (2007) Elevated risk of lung cancer among people with AIDS. AIDS 21:207–213PubMedCrossRef

25.

Pakkala S, Ramalingam SS (2010) Lung cancer in HIV-positive patients. J Thorac Oncol 5:1864–1871PubMedCrossRef

26.

Levine AM, Seaberg EC, Hessol NA et al (2010) HIV as a risk factor for lung cancer in women: data from the Women’s Interagency HIV Study. J Clin Oncol 28:1514–1519PubMedCrossRef

27.

Pakkala S, Chen Z, Rimland D et al (2011) Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer. doi:10.1002/cncr.26242

28.

Cadranel J, Garfield D, Lavole A et al (2006) Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 61:1000–1008PubMedCrossRef

29.

Lavole A, Epaud C, Rosencher L et al (2007) Lung cancer in HIV-positive patients. Rev Pneumol Clin 63:167–175PubMedCrossRef

30.

Cotter SE, Grigsby PW, Siegel BA et al (2006) FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 65:720–725PubMedCrossRef

31.

Chak LY, Gill PS, Levine AM et al (1988) Radiation therapy for acquired immunodeficiency syndrome-related Kaposi’s sarcoma. J Clin Oncol 6:863–867PubMed

32.

Cooper JS, Fried PR, Laubenstein LJ (1984) Initial observations of the effect of radiotherapy on epidemic Kaposi’s sarcoma. JAMA 252:934–935PubMedCrossRef

33.

Makinson A, Pujol JL, Le Moing V et al (2010) Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol 5:562–571PubMedCrossRef

34.

Rowinsky E, Donehower R (1997) Pharmacology of cancer chemotherapy—antimicrotubule agents. In: De Vita VT, Hellman S, Rosember SA (eds) Cancer principles and practice of oncology, 5th edn. Lippincott–Raven, Philadelphia, pp 467–483

35.

Aberg JA (2009) Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 50:54–64PubMedCrossRef

36.

Huang J, Meixner L, Fernandez S et al (2009) A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 23:51–57PubMedCrossRef

37.

Bolland MJ, Grey AB, Horne AM et al (2007) Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 92:1283–1288PubMedCrossRef

38.

Silverberg MJ, Neuhaus J, Bower M et al (2007) Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 21:1957–1963PubMedCrossRef

39.

Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523–530PubMedCrossRef

40.

Karp J, Profeta G, Marantz PR et al (1993) Lung cancer in patients with immunodeficiency syndrome. Chest 103:410–413PubMedCrossRef

41.

D’Jaen GA, Pantanowitz L, Bower M et al (2010) Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 11:396–404PubMedCrossRef

42.

Spano JP, Massiani MA, Bentata M et al (2004) Lung cancer in patients with HIV Infection and review of the literature. Med Oncol 21:109–115PubMedCrossRef

43.

Hakimian R, Fang H, Thomas L et al (2007) Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2:268–272PubMedCrossRef

44.

Massera F, Rocco G, Rossi G et al (2000) Pulmonary resection for lung cancer in HIV-positive patients with low (<200 lymphocytes/mm(3)) CD4(+) count. Lung Cancer 29:147–149PubMedCrossRef

45.

Ou SH, Ziogas A, Zell JA (2009) Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 4:1083–1093PubMedCrossRef

46.

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRef

47.

Mitsudomi T, Morita S, Yatabe Y et al (2009) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128PubMedCrossRef

48.

Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967PubMedCrossRef

49.

Rosell R, Moran T, Carcereny E et al (2009) Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol 12:75–80CrossRef

50.

Antoniou T, Tseng AL (2005) Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44:111–145PubMedCrossRef

51.

Alshafie MT, Donaldson B, Oluwole SF (1997) Human immunodeficiency virus and lung cancer. Br J Surg 84:1068–1071PubMedCrossRef

52.

Bertolaccini L, Lybéris P, Soncini S et al (2008) Clinical characteristic lung cancer in HIV-infected patients. Cancer Therapy 6:903–906

Titel: Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection
verfasst von: Yusuke Okuma
Naoki Yanagisawa
Yusuke Takagi
Yukio Hosomi
Akihiko Suganuma
Akifumi Imamura
Mari Iguchi
Tatsuru Okamura
Atsushi Ajisawa
Masahiko Shibuya
Publikationsdatum: 01.10.2012
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2012
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0316-1

Springer Medizin

Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection